rebound positive rapid test after paxlovid series; This spontaneous case was reported by an other health care professional and describes the occurrence of COVID-19 (rebound positive rapid test after paxlovid series) in a 48-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 016M20A and 029L20A) for COVID-19 vaccination.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for an unknown indication.    No Medical History information was reported.   On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Feb-2021 at 12:00 PM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 25-Oct-2021 at 10:00 AM, the patient received third dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) 1 dosage form. In May 2022, the patient experienced COVID-19 (rebound positive rapid test after paxlovid series). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 14-May-2022 to 19-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (rebound positive rapid test after paxlovid series) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In May 2022, SARS-CoV-2 test: positive (Positive) Positive.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  The patient had cough and sore throat, with rebound positive rapid test after paxlovid series. Company comment: This spontaneous case concerns a 48-year-old male patient with no reported medical history, who experienced the unexpected, non-serious adverse event of special interest COVID-19 (with a positive SARS-CoV-2 test). The event occurred after administration of two initial doses of mRNA-1273 and third dose of Pfizer, the exact date of onset of the event was not specified. The interval between the two doses of mRNA-1273 is 29 days. The patient started treatment regimen with Paxlovid on May 14-19, 2022, it has been reported that patient had cough and sore throat, with rebound positive rapid test after the treatment. Outcome of the events was unknown at the time of this report. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.; Sender's Comments: This spontaneous case concerns a 48-year-old male patient with no reported medical history, who experienced the unexpected, non-serious adverse event of special interest COVID-19 (with a positive SARS-CoV-2 test). The event occurred after administration of two initial doses of mRNA-1273 and third dose of Pfizer, the exact date of onset of the event was not specified. The interval between the two doses of mRNA-1273 is 29 days. The patient started treatment regimen with Paxlovid on May 14-19, 2022, it has been reported that patient had cough and sore throat, with rebound positive rapid test after the treatment. Outcome of the events was unknown at the time of this report. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.